Endocrinology > > Type 2 Diabetes– GLP-1 receptor agonist substantially slowed development over 6 months
by Kristen Monaco, Senior Staff Writer, MedPage Today March 13, 2024
Last Updated March 14, 2024
Liraglutide (Victoza), a type 2 diabetes drug, might assist avoid peripheral artery illness (PAD) development, the little, open-label STARDUST trial recommended.
Over 6 months, grownups with type 2 diabetes on subcutaneous liraglutide had a considerably higher boost of transcutaneous oxygen pressure (TcPO2) compared to standard treatment (14.2 mmHg vs 2.9 mmHg, approximated treatment distinction 11.2 mmHg, 95% CI 8.0-14.5 mmHg), according to Maria Ida Maiorino, PhD, of the University of Campania Luigi Vanvitelli in Naples, Italy, and associates.
An overall of 89% of liraglutide clients attained the coprimary endpoint– a 10% boost of TcPO2 from standard– versus just 46% of the control group (relative threat 1.91, 95% CI 1.26-2.90), the scientists reported in JAMA Network Open
“According to these information, we might anticipate that the administration of GLP-1 RAs [receptor agonists] might represent a correct technique in clients with PAD and diabetes, identifying a decrease or a hold-up of the start of lower-extremity problems,” they composed. “This finding might matter in the avoidance of PAD medical development since the medical diagnosis of PAD frequently accompanies the look of important limb anemia or gangrene, which generally lead to lower-extremity amputation.”
PAD-related amputation in individuals with diabetes frequently results in irreversible impairment and includes a considerable financial problem to the health care system, they explained.
The scientists kept in mind that the boost in TcPO2 “corresponded in time within the liraglutide group, with considerable distinctions compared to the people randomized to the control group,” including that this was the very first trial of clients with type 2 diabetes and PAD to reveal that liraglutide increased peripheral perfusion.
“Liraglutide, in addition to other GLP-1 RAs, might identify its impact on peripheral perfusion through both microvascular and macrovascular systems,” they composed. “Liraglutide works on glycometabolic outlook, which impacts the cardiovascular threat profile.”
“We selected liraglutide due to the fact that it was the GLP-1 receptor agonist with the higher number of proof about lower extremity issues, at the time of the procedure preparing,” Maiorino informed MedPage TodayWhile this might possibly be a class impact with all GLP-1 receptor agonists, she stated it requires to be verified in future research studies.
Developed for type 2 diabetes, GLP-1 RAs have actually just recently ended up being popular for weight management. Liraglutide was at first authorized by the FDA in 2010 at the 1.8-mg dosage for type 2 diabetes. At the 3-mg dosage, liraglutide (Saxenda) was authorized for persistent weight management in 2014 for grownups, which was reached teenagers in 2020.
More just recently, this class of representatives has actually moved into the cardiovascular defense area, with the GLP-1 receptor agonist semaglutide (Wegovy) authorized to lower the threat of cardiovascular death, cardiovascular disease, and stroke in grownups with heart disease and either weight problems or obese.